Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
NCT03022500Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2017
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in pulmonary sarcomatoid carcinoma (PSC), sponsored by Seoul National University Hospital. Started May 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT03022500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022500.